Chronic Pain Relief Without Addictive Opioids: Cannabidiol (CBD)
Most people are aware of the staggering opioid (opiate) crisis. A recent study projected that 1.2 million people in the U.S. and Canada will die from opioid overdoses unless there is urgent intervention. Since 1999, more than 600,000 people have died in North America and addictions are rising steadily in the United Kingdom, the Netherlands and Israel.
This is a global problem – and the concern is that it is irreversible for many people. By now you’ve no doubt read about how some pharmaceutical companies, in the mid-1990s, began promoting drugs like OxyContin, Percocet, Tylenol #3 and others to treat chronic pain, glossing over just how insidiously addictive these products can be and their long-term harm.
The key issue at the heart of this crisis is pain, especially chronic pain. It can be intolerable and pain comes in many forms, especially with an aging population: as many as 1 in 4 Canadians over age 50 battle chronic pain. Globally, it’s a leading cause of disability and is a major factor impacting quality of life, decreased social connections and lost productivity. Most people treating chronic pain start with acetaminophen (Tylenol) or NSAIDS (e.g. ibuprofen, naproxen, indomethacin, etc.). However, higher doses of these drugs over a long period of time can cause serious gastrointestinal side effects including bleeding. Most patients and their doctors are left with few options other than opioids to control the chronic pain.
However, there are safe, effective, and non-addictive alternatives for pain management that promise additional relief without the risks of long-term opioid use: cannabinoids such as CBD.
Cannabinoids are proven to play a role in relieving inflammatory and neuropathic pain. CBD (cannabidiol) and THC (tetrahydrocannabinol) are two common cannabinoids found in cannabis that control inflammation that causes pain and can help inhibit the sensation of pain. There is mounting evidence to support their safe use in treating chronic pain.
Opticann uses patented pharmaceutical technology, VESIsorb®, in its CB4 Relief-T softgels with 25 mg CBD, 13 mg BCP (a terpene with anti-inflammatory properties) and only 0.75 mg of THC.
CB4 Relief-T softgels are fast acting and long-lasting. VESIsorb® is clinically proven to increase absorption (potency) of CBD by 440% (4.4x) and enables 3 times faster onset of action than conventional CBD capsules.1 The low concentration of THC minimizes the risk of intoxication.
All Opticann CB4 products are developed with innovative pharmaceutical technology and are scientifically tested to provide maximum benefits, quickly. CB4 Relief-T softgels were clinically tested and the results published in a scientific peer reviewed journal.1
CARP members receive 15% off all Opticann CB4 products. All members require a medical document to purchase products from Opticann.ca.
Go to Opticann.ca to consult with our clinic (free) to be assessed for a medical document.
Additionally, and for a limited time only for new patients, buy 1 bottle of CB4 Relief-T capsules and get the second for 40% off.
To learn more, please go to Opticann.ca or call Opticann Patient Care at 1-855-437-2266.
1 Knaub, K. et al. (2019). A novel self-emulsifying drug delivery system (SEDDS) based on VESIsorb® formulation technology improving the oral bioavailability of cannabidiol in healthy subjects. Molecules, 24(16): 2967. https://doi.org/10.3390/molecules24162967